The future of GLP-1s, a class of medications, is being considered in various contexts, including their use in weight loss and potential changes in coverage under medicare and medicaid. Some outlets are reporting on the potential expansion of access to these medications, while others are discussing the costs and issues associated with their coverage. The development and market for obesity drugs, including GLP-1s, appears to be evolving, with new medications and potential combinations being explored.